In our cohort, which included 203 HGOC women who had not undergone prior germline analyses, 45 patients showed BRCA1/2 pathogenic or likely pathogenic variants (henceforth termed as PVs) at tumour testing (31 BRCA1, 14 BRCA2). This evidence concerns the gene BRCA2 and neoplasm.